Websites:
http://www.sciencepub.net
http://www.sciencepub.net/report

Emails:
editor@sciencepub.net
reportopinion@gmail.com

Report and Opinion

MARSLAND PRESS
Multidisciplinary Academic Journal Publisher

A review on bipolar disorder and its treatment

Saba Irfan[1*], Mohsin Nawaz[1], Sawera Nayyab[1*], Akasha Islam[1], Fatima Nadeem[1], Amna Kousar[1], Hina Illyas[1], Aimen Afzal[1], Sheherbano[1], Aleena Waheed[1], Amal Ijaz[1], Iqra Aziz[1], Sadaf Faisal[1], Savera mehak[1]

[1]Department of Biotechnology University of Gujrat, Sialkot, Pakistan
*Corresponding author's: sawera.nayyab@uogsialkot.edu.pk isaba4709@gmail.com

Abstract: Bipolar disorders (BPD) are major, life - long psychiatric illnesses found in 2–5% of the population. It is characterised by the occurrence of one or more manic or hypomanic episodes, usually alternating with depressive episodes. While the causes of bipolar disorder are not clearly understood, both genetic and environmental factors are thought to play a role. Genetic factors account for about 70–90% of the risk of developing bipolar disorder. Environmental risk factors include a history of childhood abuse and long-term stress. Mood stabilizers-lithium and certain anticonvulsants such as valproate and carbamazepine—are the mainstay of long-term relapse prevention. Antipsychotics are given during acute manic episodes as well as in cases where mood stabilizers are poorly tolerated or ineffective or where compliance is poor. There is some evidence that psychotherapy improves the course of this disorder. The use of antidepressants in depressive episodes is controversial. Electroconvulsive therapy (ECT) is effective in acute manic and depressed episodes, especially with psychosis or catatonia.
[Saba Irfan, Mohsin Nawaz, Sawera Nayyab, Akasha Islam, Fatima Nadeem, Amna Kousar, Hina Illyas, Aimen Afzal, Sheherbano, Aleena Waheed, Amal Ijaz, Iqra Aziz, Sadaf Faisal, Savera mehak. **A review on bipolar disorder and its treatment.** *Rep Opinion* 2020;12(9):41-53]. ISSN 1553-9873 (print); ISSN 2375-7205 (online). http://www.sciencepub.net/report. 9. doi:10.7537/marsroj120920.09.

Key words: Bipolar disorders, manic, Electroconvulsive therapy (ECT)

Introduction:

Audit articles for adults6, 7 and paediatric patients8 suggest advance, however we have not completely investigated depressive scenes, mix treatment, wellbeing administrations mediations, and exceptional populaces. Practice guidelines,9 choice trees, 10 and expound algorithms11,12 are elegantly composed, however are not easy to understand. abnormal elevated mood. [1] these elevated mood condition also known as mania its depends upon the severity of condition some time can led to psychosis. [2] during bipolar the victim experience very negative thinking and feel very negative about life and also reduce sleep and make some very nonsense decisions regardless of consequences. The percentage of suicide among the victims is about 6% in 20 year person while in older people they mostly harms themselves. [3] I have studied four medicines of the treatment of bipolar disorders are **lithium** carbonate, **valproic acid, carbamazepine and lamotrigine**. More pharmacologic alternatives are presently accessible, and psycho education, self improvement, and psychotherapy (individual, couple, and family) mediations are every now and again utilized. [9] The Depression and Bipolar Support Alliance has played a main part in teaching patients, their families, therapeutic experts, emotional well-being experts, and people in general everywhere about hyper depressive ailment. The National Alliance of the Mentally Ill (NAMI) has likewise looked for data by studying relatives about usage and estimation of psychological well-being services [13].

Epidemiology

The disorder mainly onset in age between 18 to 22 but some studies showed that the onset can happen between the age of 18 to 45. In between 18 to 33 the % of onset is higher as compare to 33 to 55. [14] In an overview of individuals from the DBSA, the greater part of the patients did not look for nurture five years and the right determination was not made until a normal of eight years after they initially looked for treatment [15]. There is no constant association between bipolar and secede myography factors. The rate of bipolar disorder is more in unmarried people and the both the female and male effected in the same the % is same. Economic analyses typically incorporate direct treatment costs, roundabout expenses emerging from mortality, and circuitous costs identified with dreariness and lost profitability. This is the model for bipolar turmoil and others that are long haul or lifetime issue. Misdiagnosis prompts extreme expenses and mistreatment. [8] Late introduction, insufficient analysis, and under treatment contribute intensely to costs.

Aetiology and Patho physiology

Biochemical investigations are in progress for transmitters (catecholamines, serotonin, gamma aminobutyric corrosive (GABA), glutamate and others), hormones (mind determined neurotrophic factor, thyroid and others), and steroids—alone and in coordinated effort. Imaging ponders, developing all through pharmaceutical, may reveal insight. [15]

Symptoms

In past it just as normal depression but with time it become more studied and need to be have special treatment for the bipolar. In bipolar antidepressant do not work but it also enhances the situation and become the cause of other types and also reason for mod destabilization. Some common symptoms are [16]. Feeling hopeless, Feelings of worthlessness or guilt, sad, or empty, Irritability, Inability to experience pleasure, Sleep problems, Fatigue or loss of energy, Appetite or weight changes, Physical and mental sluggishness, Concentration, memory problems and Thoughts of death or suicide [17].

Treatment

The American Psychiatric Association (APA) built up the Practice Guideline for the Treatment of Patients with Bipolar Disorder. [18] The standards of mental administration are illustrated in Table 2. A helpful organization together is urgent for comprehension and dealing with the patient, recognizing repeat of disease, improving adherence, and tending to psychosocial stressors. Patients require progressing training with respect to the disease, treatment choices, and the effect of the ailment on social and family connections, work, and budgetary issues. Realistic portrayal of the ailment is a strategy to unite data (scene grouping, extremity, seriousness, recurrence, and relationship to stressors and treatment), teach the patient, and may build up an alliance. [19] For patients who are thinking about kids or are pregnant, basic leadership is best done in the restorative relationship. [20] I have studied four medicines of the treatment of bipolar disorders are **lithium** carbonate, **valproic acid, carbamazepine** and **lamotrigine**

Lamotrigine

At that time data on long term use of lamotrigine on patients that were suffering from bipolar disorder is very limited. Mostly the patients that were suffered from bipolar disorder are prescribed to go through the lamotrigine treatment because it is saving. The study shown that the treatment with combination of lamotrigine and antidepressant show very impressive results. It mostly work against bipolar II as compare to bipolar I. [21]

5HT Receptor

The effect of Lamotrigine on human body a pilot scale study have been done in which the Lamotrigine given in the combination SSRI's this combination IS FAR MORE better then the only use of SSRI's treatment [22]. Lamotrigine basically stabilizer the mood by down regulate the cortical 5-HT_{1A}-receptor [23] For quantifying 5-HT_{1A}, 5-HT_{1B}, and 5-HT_{2A} m-RNA levels in the hippocampus and dorsal prefrontal cortex the technique in situ hybridization is use that show the a very effective difference in the mRNA level and show how the receptor were down regulated [24] it reasoned that 5-HT firing in the DRN is diminished however 5-HT transmission in the forebrain is upgraded by managed carisbamate and lamotrigine organization. [25] The consequent investigations demonstrated that exclusive a high proclivity postsynaptic5-HT1A receptor agonists, apresynaptic what's more, postsynaptic 5-HT1A/1B receptor opponent sand to lesser broaden postsynaptic 5-HT1A/1B agonists could improve the upper like impact of lamotrigine [26] Cortical 5-HT1A receptor mediated down direction of response seal so proposes another conceivable system of activity of lamotrigine [27].

Effect of Lamotrigine on the Noradrenergic Receptors

It was discovered that when higher measurement this inhibitor was given in mix with lamotrigine, it delivered narcotic impact, which was thought to be in charge of the inversion of the energizer like impact of lamotrigine. Such inversion of the counter fixed status impact was likewise found at bring down measurements of α-methyl-p-tyrosine. [28] Brief inversion in the upper reaction to desipramine, mazindol, and mirtazapine was delivered by the intense organization of a-methyl-p-tyrosine [29] Lamotrigine was likewise answered to hinder the synaptosomal take-up of serotonin, nor adrenaline, and dopamine in the cerebrum which could bean sign that lamotrigine in a nearly way influences the nor adrenergic system, by the arrival of nor adrenaline, which could additionally bring about connection with the receptors [30] the later investigation directed on the inclusion of noradrenergic framework in the stimulant like activity of lamotrigine detailed that in spite of these adrenergic medications demonstrating narcotic impacts [31]

Absorption of lamotrigine

The assimilation of lamotrigine after oral administration is quick, entire and unaffected by nourishment ingestion. It experiences insignificant first-pass metabolism, and has an of 98% bioavailability [32].

The clearance of the lamotrigine

The clearance of the lamotrigine depend on the dose of the today approximately 100-700 mg it mean disposal half life is nearly in a day in solid person [33] clearance may be lower if the person have hepatic or

renal impairment smoking age sex have been not affect the rate of clearance [32].

Excretion

Lamotrigine essentially undergoes hepatic metabolization through glucuronidation, producing inactive metabolites that mainly consist of lamotrigine 2N-glucuronide and to a lesser extent the 5N-glucuronide, N-oxide and N-methyl metabolites, which are all renal, excreted [34] these incorporate the particular bar of the N-and P-type calcium diverts in central brain areas, and the voltage-subordinate bar of sodium channels by means of its activity on the moderate inactivation express that happens when sodium channels are over-actuated. Lamotrigine has additionally been appeared to restrain the arrival of excitatory amino acids, for example, glutamate and aspartate, and may have some agonistic impacts on γ-aminobutyric corrosive (GABA) [35]

Limitation

In spite of its demonstrated significance in bipolar disorder, several constraints are likewise shown by lamotrigine as detailed by a few investigations. The information acquired from a controlled clinical preliminary utilizing fake treatment indicated positive outcomes for lamotrigine just in patients with bipolar II issue. A twofold visually impaired fake treatment controlled clinical preliminary was led affirmed that the dosages extending from 50 to 200 mg/day was observed to be exceptionally compelling in bipolar discouragement, anyway the viability as appeared by the Hamilton wretchedness scale was not noteworthy. Lamotrigine was additionally answered to indicate negative outcomes in intense insanity according to the outcomes acquired from two twofold blinded fake treatment controlled investigations [36] Treatment of bipolar II misery with adjunctive lamotrigine may likewise be related with a past filled with suicide-endeavors and various melancholy related earlier hospitalization if there should arise an occurrence of poor reaction to the adjunctive lamotrigine treatment, according to the data from the 52-week follow-up think about. If there should arise an occurrence of a past filled with past hospitalization, an expanded danger of re hospitalization, treatment obstruction, and depressive backslide was accounted for [37] In patients with bipolar disorder, lamotrigine anyway does not demonstrate any impeding effect on the neurocognitive capacities, in this way guaranteeing the protected and long haul utilization of lamotrigine in bipolar confusion. At the time of initiation of the treatment slow titration of the lamotrigine dose could decrease the inherent risk and incidence of rashes. In patients with bipolar disorder, lamotrigine however does not show any detrimental impact on the neurocognitive functions, thereby ensuring the safe and long-term use of lamotrigine in bipolar disorder [38]

Lithium

The state of mind stabilizer lithium has been the standard pharmacological treatment for BD for more than 60 years. Its acquaintance drove with a quick change in result for some, patients experiencing this sickness whose treatment alternatives had, until that point, been very bleak. Lithium was found be compelling in treating intense hyper and depressive scenes, and also in diminishing the repeat of mind-set scenes and limiting the danger of self-destructive practices [39] Lithium is the lightest of all metals, with a density just a large portion that of water. It initiates various biochemical and atomic impacts on neurotransmitter/receptor- interceded, hormonal and circadian control, particle transport, and quality expression signaling, flag transduction falls [40]

Lithium's neurotrophic effects on pathways which are more responsible for the bipolar disorder

GSK-3 pathways targeting at the PI cycle, PKC, and MARCKS:

Glycogen synthase kinase 3 (GSK-3)

GSK-3 is a serine/threonine kinase that controls assorted cell forms and straight forwardly directs cell apoptosis. Enthusiasm for GSK-3 as an objective for BD sedate advancement emerged from discoveries that it is critical to various focal capacities, for example, glycogen amalgamation, quality interpretation, synaptic versatility, apoptosis (cell passing), cell structure and strength, and the circadian cycle [41] these capacities are fundamentally embroiled in the pathophysiology of extreme repetitive temperament issue. In fact, Benedetti and colleagues demonstrated that a polymorphism in the GSK-3 quality was related with before beginning of BD. [42] The downstream focuses of GSK-3 are many, and the subsequent practical outcomes of GSK-3 actuation or restraint regularly rely upon the flagging pathway focused on. For instance, GSK restraint by the Wnt pathway actuates the transcription factor β -catenin. Different focuses of GSK-3 incorporate translation factors like c-Jun, proteins bound to micro tubules (MAP), cell cycle arbiters and controllers of digestion [43] GSK-3also specifically directs diverse neurotransmitter frameworks engaged with the pathophysiology of BD, for example, the dopaminergic, glutamatergic, and serotonergic frameworks [44]

Lithium's neurotrophic effects targeting at GSK-3 pathways

pathways—GSK-3 hindrance is normally connected with the neurotrophic impacts of various survival factors. GSK-3 restraint straight forwardly impacts quality interpretation, prompting against apoptotic impacts and enhanced cell auxiliary

solidness [45]. Outstandingly, GSK-3 was appeared to be downregulated by lithium in assorted examinations, initiating direct neuronal security against various wounds [46] lithium inhibits GSK-3 with an enzyme inhibition constant (Ki) of 1–2 mM (serum therapeutic range 0.6–1.2 mM) [47] Akt activation and indirect inhibition of GSK-3 by lithium have also been demonstrated after acute or chronic treatment with therapeutically relevant levels of lithium [48] exhibited that thumping out a solitary duplicate of the GSK-3β quality in mice brought about upper like impacts that were similar to lithium organization. Additionally, fringe organization of a GSK-3 inhibitor decreased amphetamine-incited hyperactivity [49].



Focuses for lithium's neuroprotective impacts. Targets appeared in orange are primarily ace apoptotic proteins/receptors; lithium either fundamentally downregulates these proteins or declines their demeanor. Against apoptotic proteins are appeared in blue. Lithium expands their appearance and additionally levels, in this way inciting neuroprotective and neurotrophic impacts. Actuation of cerebrum neurotransmitter-coupled G-proteins instigates PLC hydrolysis of PIP2 to IP3 and DAG (not appeared), which initiates PKC. IP3 ties to the IP3R, along these lines instigating the arrival of ER calcium stores. Expanded intracellular calcium levels have been portrayed in bipolar confusion and may increment the danger of apoptosis. The neuroprotective protein Bcl-2 downregulates ER calciumrelease through an IP3R-subordinate component. A similar impact is actuated by lithium treatment, which likewise expands Bcl-2 levels. IP3 is reused by IMPase, another of lithium's objectives. Cell motioning through Wnt glycoproteins and frizzled receptors result in GSK-3β restraint, a basic cell target and defector for assorted proteins. Hindrance of GSK-3β avoids β-catenin phosphorylation and fortifies its translocation to the core, along these lines focusing on translation of particular qualities actuating neurotrophic impacts and synaptogenesis. Enactment of the BDNF receptor (Trk-B) actuates the ERK/MAPK pathway, which represses GSK-3β and BAD. Enactment of the ERK/MAPK pathway by

BDNF expands the outflow of atomic CREB, which encourages the statement of neurotrophic/neuroprotective proteins, for example, Bcl-2 and BDNF. BDNF additionally initiates the PI3K pathway, which in a roundabout way hinders GSK-3β and BAD. Mitochondrial Bcl-2 and Bcl-xl additionally restrain proapoptotic actuation of BAD, and also resulting mitochondrial increment of calcium convergence and cytochrome C release. Bcl-2 = B-cell lymphoma-2; BDNF = brain-derived neurotrophic factor; Ca2+ = calcium; CREB = cAMP response element binding protein; Cyt C = cytochrome C; DAG = diacylglycerol; ER = endoplasmic reticulum; ERK = extracellular regulated kinase; GSK = glycogen-synthase kinase; IMPase = inositol monophosphatase; IP3 = inositol 1,4,5-triphosphate 3; IP3R = inositol 1,4,5-triphosphate 3 receptor; Mg2+ = magnesium; MAPK =mitogen activated protein kinase; NMDA = N-methyl D-aspartate; NT = neurotransmitter; PI3K = phosphatidylinositol-3 kinase; PIP2 = phosphoinositide 4,5-biphosphate; PKC =protein kinase C; PLC = phospholipase C; PTP = permeability membrane pore; TrkB = tyrosine receptor kinase B.

Experiment preformed to show lithum in PI

Studies have since exhibited the legitimacy of this theory as a clarification for the restorative activity of lithium; attractive reverberation spectroscopy (MRS) discoveries have demonstrated unusual PI-cycle action and raised myo-inositol fixations in patients with bipolar scatters [50] along these lines it takes after that lithium conceivably applies a remedial impact by influencing cell motioning because of IMPase restraint, and resulting diminishment of hoisted inositol and phosphatidylinositol levels [54]



Inositol exhaustion inside the PI flagging pathway. An agonist ties to a receptor complex, comprising of a receptor, Gq-protein and phospholipase (PLC). PLC hydrolyses the phospholipid phosphatidylinositol 4,5-biphosphate (PIP2) to shape two second couriers: inositol-1,4,5 triphosphate (IP3) and 1,2-diacylglycerol (DAG). IP3 ties to particular receptors to help open the calcium

(Ca2+) channel and DAG starts enactment of protein kinase C (PKC). IP3 is consecutively separated into inositol bisphosphates (IP2) and afterward inositol monophosphates (IP). IP is at last separated into myo-inositol by the compound inositol monophosphatase (IMPase). Lithium restrains IMPase, prompting myo-inositol exhaustion. Myo-inositol is likewise the substrate for combination of phosphatidylinositol (PI), which is phosphorylated to shape mono-, bis-and tris-phosphatidylinositol. Lithium actuated myo-inositol exhaustion accordingly keeps the resynthesis of PIP2 and consequent recovery of IP3 and DAG, influencing cell flagging.

Mood of action Not at all like numerous other psychopharmacological operators, for example, customary antidepressants and antipsychotics, it doesn't tie to cell receptors; rather, lithium seems to apply restorative activities through change of intracellular second detachment frameworks, downstream of metabotropic neurotransmitter receptors, by means of chemical hindrance [55].

Quetiapine

Quetiapine first got FDA endorsement in 1997 for the treatment of intense scenes of schizophrenia in grown-ups. The pharmacological properties of this pharmaceutical before long prompted utilizes as a part of other neuropsychiatric conditions specifically full of feeling issue, uneasiness issue, extreme introvertedness range issue, dementia and wooziness [56] Adequacy in two fold visually impaired, randomized, controlled preliminaries was the reason for the permitting of quetiapine in bipolar lunacy, bipolar despondency, bipolar upkeep and significant depressive issue either as monotherapy or adjunctive to other prescription [57] Presently quetiapine has turned out to be a stand out amongst the most regularly endorsed drugs for bipolar patients and is utilized as a part of all periods of BD [58]

Metabolism of quetiapine

Quetiapine is widely utilized by the liver into different metabolites with just 1% discharged unaltered in the pee. N-desalkyl quetiapine or norquetiapine is quetiapine's key metabolite and is delivered by the activity of isoenzymes CYP 3A4 in the cytochrome P450 framework [59] Minor metabolism occurs via CYP2D6 into 7-hydroxy quetiapine which is thought not to possess any active properties. The efficacy of quetiapine in treating psychotic disorders as well as mood and anxiety disorders leads to the view that it is a multifunctional psychoactive drug. Its broad spectrum of efficacy is likely due to its ability to modify systems of dopaminergic, serotonergic and noradrenergic neurotransmission and its effects appear to be mediated by the actions of both quetiapine and norquetiapine.

Mood of action

The bar of dopamine D2 receptor in the mesolimbic pathway is thought to be the principle system behind antipsychotic adequacy. Both quetiapine and norquetiapine tie with direct proclivity to D1 and D2 receptors, also the previous quickly separates from D2 receptors clarifying the requirement for organization of high measurements of quetiapine to realize its antipsychotic impact. [60] It additionally displays low limit with regards to up-control of these receptors, which clarifies the low rate of tardive dyskinesia related with delayed quetiapine treatment. In the nigrostriatal and tuberoinfundibular dopamine pathways serotonin appears to go about as an inhibitory modulator by its activity on 5HT2A receptor. Both quetiapine and norquetiapine firmly threaten this receptor, in this way facilitating dopamine discharge in the said pathways and bringing about low rate of extrapyramidal reactions and hyperprolactinemia [61] Numerous indications of gloom like anhedonia, psychomotor impediment, social withdrawal and loss of inspiration result from diminished dopamine neurotransmission in the prefrontal cortex (PFC). It is trusted that norquetiapine with its 5HT2A and 5HT2C opposition encourages dopamine discharge in PFC and is instrumental in alleviating the depressive side effects in patients with state of mind issue [62] Quetiapine, and to a more noteworthy degree its metabolite norquetiapine encourage serotonergic transmission by carrying on as fractional agonists at 5HT1A receptors which are related with stimulant and anxiolytic impacts in people. Norquetiapine has a high fondness for 5HT1A receptors, like that of ordinary agonists' buspirone and gepirone. Through this component it increments serotonergic neurotransmission by the raphe neurons in the mind stem and additionally balances 5HT working in the limbic and cortical areas [63] By activating the 5HT1A receptors in the hippocampus, norquetiapine can spur neuron regeneration by increasing the release of trophic factors like the brain-derived neurotrophic factor [64] Norquetiapine additionally has a higher liking for 5HT7 receptor than quetiapine. This current receptor's inclusion in sadness and rest related, circadian musicality issue has been tentatively reported, and it is conceivable that norquetiapine's 5HT7 receptor opposition adds to quetiapine's energizer activity. [65]

Limitations

The receptor restricting profile of quetiapine and its dynamic metabolite norquetiapine clarifies the antagonistic impacts of these substances. Them two tie to histamine H1 receptors causing sedation, mesmerizing impacts, expanded hunger and weight pick up. Blockage of alpha 1 receptors by both these mixes clarifies the orthostatic hypotension experienced

by a few patients. Norquetiapine goes about as a solid enemy at muscarinic M1, M3, and M5 receptors with the goal that anticholinergic impacts like dry mouth, urinary maintenance, pupillary dilatation, raised intraocular weight, and hypothermia result from the activity of this dynamic metabolite. A few specialists are of the view that hyperglycemia and diabetes caused by quetiapine treatment are essentially the consequence of M3 receptor enmity. [66]

Quetiapine Treatment of BD

Concentrates on the longitudinal course of BD demonstrated that patients invested substantially more energy experiencing depressive side effects when contrasted with hyper manifestations [67] The previous could be as intense MDE which may require hospitalization or ceaseless sub edge side effects with complex comorbidities like tension range issue, substances utilize clutters, dietary issues and stressor-related scatters [68] On account of these insights it was basic to discover viable medications for the depressive period of BD. Various investigations demonstrated that quetiapine monotherapy was a useful treatment for intense bipolar misery at any rate in grown-up patients of both genders. [69] The EMBOLDEN I consider thought about the viability and averageness of quetiapine and lithium monotherapy with that of fake treatment for a MDE in BD. Eight hundred and two patients with DSM-IV characterized BD (499 bipolar I, 303 bipolar II) were haphazardly allotted to quetiapine 300 mg/day (n=265), quetiapine 600 mg/day (n=268), lithium 600–1,800 mg/day (n=136), or fake treatment (n=133) for two months. Essential endpoint was the change in MADRS add up to score. The examination was led from August 2005 to May 2007. The outcomes demonstrated that the mean MADRS add up to score transform from the pattern at two months was −15.4 for quetiapine 300 mg/day, −16.1 for quetiapine 600 mg/day, −13.6 for lithium, and −11.8 for fake treatment. Quetiapine 600 mg/day was fundamentally more powerful than lithium in enhancing MADRS add up to score at week 8. Quetiapine treated (the two measurements), however not lithium treated, patients indicated critical enhancements ($p<0.05$) in MADRS reaction and abatement rates, Hamilton Rating Scale for Depression (HRSD), Clinical Global Impressions-Severity of sickness and - Change, Hamilton Rating Scale for tension (HAM-A) scores at week 8 versus fake treatment. Both quetiapine dosages were more viable than lithium on the HRSD and HAM-An at week 8. The examination presumed that quetiapine (300 or 600 mg/day) was more successful than fake treatment for the treatment of intense scenes of sorrow in BD. Lithium did not vary essentially from fake treatment on the fundamental measures of adequacy [70].

Quetiapine in Bipolar Maintenance

BD is a very repetitive condition with backslides that could be depressive, hyper or blended in nature. There are few affirmed medications to counteract repeats in BD; one such alternative is quetiapine adjunctive to lithium or divalproex sodium for the support treatment of BD. In an examination of two huge randomized, fake treatment controlled preliminaries the security and viability of quetiapine joined with lithium or divalproex for averting temperament occasions in patients with bipolar I issue was resolved. In this pooled examination, patients got open mark quetiapine (400– 800 mg/day) in addition to lithium or divalproex to accomplish no less than 12 weeks of clinical solidness before being randomized to twofold visually impaired blend treatment with quetiapine (400– 800 mg/day) or fake treatment in addition to lithium or divalproex for up to 104 weeks. The essential endpoint was an ideal opportunity to first disposition occasion post randomization following open adjustment. The after effects of the investigation demonstrated that of the 3,414 patients in the adjustment stage, 1,326 were randomized. There were no distinctions in the danger of repeat of state of mind occasions, insanity or despondency between quetiapine in addition to lithium or quetiapine in addition to divalproex. Among patients co-treated with fake treatment and lithium, the danger of repeat of a madness occasion was altogether higher than among patients co-treated with fake treatment and divalproex. In patients with a file scene of craziness, fake treatment in addition to lithium was related with an altogether higher danger of repeat of a lunacy occasion than fake treatment in addition to divalproex. Security information were for the most part predictable with perceived wellbeing profiles. The examination presumed that in patients with bipolar I issue beforehand balanced out on quetiapine and lithium or divalproex, upkeep treatment with quetiapine essentially expanded time to repeat of a mind-set occasion (craziness or discouragement) versus fake treatment, paying little respect to whether it was joined with lithium or divalproex. [71]

divalproex sodium

The system by which valproate applies its restorative impact isn't surely knew. A few speculations have been proposed concerning the instrument of activity in epilepsy and BD The most all around considered and comprehended instrument of valproate is its capacity to potentiate or imitate the impacts of the inhibitory neurotransmitter, gamma-aminobutyric acid (GABA) A portion of the other and less surely knew systems include the hindrance of neuronal volatility and a resultant hostile to fuel impact One particular territory of study has

concentrated on the restraint of protein kinase C epsilon (PKC-epsilon). [72]

Metabolism of divalproex sodium

Divalproex is utilized in the liver, essentially through glucuronidation to dynamic metabolites, with the significant dynamic metabolite being Trans-2-en-valproate. [72] The assessed half-existence of divalproex ranges from 9 to 16 hours [73] The standard dosing regimen for DR is on an a few times every day plan, frequently with the bigger measurement given at sleep time. The remedial range for divalproex sodium in intense madness as indicated by essential writing proposes change is most noteworthy at fixations over 50 µg/mL and that antagonistic impacts increment altogether at focuses over 125 µg/mL [74] The more common side effects of DR are transient nausea (31%), asthenia (20%), somnolence (17%), dyspepsia (13%), dizziness (12%), diarrhea (12%), vomiting (11%), and tremor (9%) [73]

Mechanism of divalproex sodium

The system by which valproate applies its remedial impact isn't surely knew. A few theories have been proposed concerning the component of activity in epilepsy and bipolar issue. The most very much examined and comprehended component of valproate is its capacity to potentiate or emulate the impacts of the inhibitory neurotransmitter, gamma-aminobutyric acid (GABA) In a roundabout way, this potentiation of GABA has been speculated to create inhibitory impacts on focal dopamine A portion of the other and less surely knew components include the hindrance of neuronal volatility and a resultant against fuel impact PKC-epsilon has been connected to the incitement of intracellular calcium discharge and an expansion in cortical excitation and unsteadiness. Valproate has additionally displayed impacts delivering the bar of voltage-subordinate sodium channels [73]

Extended-release divalproex

the most up to date plan of divalproex is as an expanded discharge tablet, Depakote ER® (ER), which gives an once-day by day organization choice for the treatment of intense hyper or blended scenes of bipolar issue, free of the nearness of crazy highlights (Abbott Laboratories 2006). The ER definition utilizes a hydrophilic polymer network controlled-discharge tablet framework to give controlled proceeded with arrival of pharmaceutical. After oral organization and section into the stomach, the external covering of the tablet breaks down and uncovered the polymer framework. The external layer of the framework ends up hydrated and shapes a gel layer from which sedate is discharged. Notwithstanding bipolar turmoil, ER is additionally endorsed for the prophylactic administration of headache cerebral pains in grown-ups, and also monotherapy and adjunctive treatment in grown-ups and kids 10 years old and more established with complex fractional seizures, grown-ups and kids 10 years old or more established with basic and complex nonattendance seizures, and grown-ups and youngsters 10 years old and more established with numerous seizure writes including nonappearance seizures Similar investigations have demonstrated that DR and ER are not bioequivalent items. The two essential active contrasts are that the ER readiness brings about a normal bioavailability of 81%– 89% with respect to DR and ER has produces a 10%– 20% lower variance in top serum focus when contrasted with DR. These discoveries recommend that while changing over patients from DR to ER that the ER measurements may should be expanded in the vicinity of 8% and 20% to deliver an identical serum fixation. [73]

Role of divalproex in bipolar disorder

In numerous examples, bipolar turmoil treatment rules prescribe valproate as a favored specialist, with DR as a rule being the recommended plan of valproate/valproic acid (divalproex) due to the assumed enhanced passableness The infection states where confirm based rules bolster the utilization of valproate as a first-line decision include: intense hyper intensifications, euphoric insanity, dysphoric or blended lunacy, and in patients being dealt with for fast cycling BD see table 2 [74].

Clinical trials efficacy

The primary preliminary examined is an open-mark, multi day contemplate assessing the adequacy and security of cThe dominant part of members conveyed an analysis of bipolar issue or significant gloom, 36% and 27% individually. Other mental determination included schizophrenia and schizoaffective issue. An aggregate of 55 patients were incorporated into the change, 75% outpatients and 25% inpatients hospitalized for intense indications. Members had been treated with DR from 2 days to >4 years at measurements of 500 to 5,000 mg/day. Accompanying medicines were portrayed and included specialists, for example, antipsychotics, antidepressants, and anxiolytics. Following pattern estimations of plasma valproic acid focuses, contemplate members were changed to ER at a measurements equivalent to their aggregate day by day dosage of DR. Consequent remedial medication observing included appraisal of plasma valproic acid fixations which were gotten 10 to 12 hours after the keep going measurements on think about days 3, 5, and 7. Over a large portion of the patients in the investigation (58%) encountered an expansion in valproic acid plasma focus when changed from DR to ER measurements shapes. In everything except three cases, plasma fixations stayed inside the restorative scope of 50– 125 µg/mL. In two of the cases the plasma levels expanded after the inception of the ER

measurement frame without any indications of poisonous quality and came back to esteems inside restorative range with dose lessening. In the third case, the patient's serum valproic acid level diminished underneath the lower furthest reaches of ordinary however expanded after measurement titration. Efficacy was evaluated with the Positive and Negative Syndrome Scale (PANSS) at gauge and endpoint. Endless supply of the aggregate patient populace, a factually critical change was seen in mean PANSS add up to score, positive subscale and general psychopathology subscale from pattern to endpoint. Mean aggregate PANSS scores at standard were 71.5 ± 21.4 with a mean difference in −4.3 ± 11.1 at endpoint. While a factual change was valued, clinical effect of change was in all probability little. Unfriendly occasions were evaluated with the Udvalg for Kliniske Undersogelser (UKU) Side Effect Rating Scale. Patients announced a diminishing in the number and seriousness of antagonistic impacts at endpoint. Following the end of the investigation, 54 of the 55 members proceed with treatment with the ER definition. Measurable power was not talked about in the investigation plan. This plan trademark turns out to be less of an issue for result measures in which factual change is watched. In general, transformation from DR to ER in this inpatient and outpatient mental populace was not related with weakening in mental status. Also, a decrease in both the frequency and seriousness of unfavorable impacts was acknowledged with the ER dosing definition, probably thought to be the after effect of lower crest focuses. A second distributed, open-name ponder featured the change of DR to ER in ten subjects over a four-week time periodonverting mental patients from DR to ER [75]

Table 2

Suggested first-line treatment strategies per available guidelines

Guidelines for the treatment of bipolar disorder							
	Non-psychotic mania	**Mixed mania**	**Dysphoric mania**	**Mania with a history of rapid cycling**	**Euphoric mania**	**Psychotic mania**	**Bipolar depression**
APA		Severe: Li plus AP OR VPA plus AP Less Severe: monotherapy Li, VPA or AP		Li OR VPA			Li OR LAM
Expert Consensus 2004	Combination MS plus AP OR Monotherapy MS	Combo therapy and monotherapy received equivalent ratings	Combination treatment and monotherapy received equivalent ratings	Combination treatment and monotherapy received equivalent ratings	MS	MS plus AP OR monotherapy AP	LAM monotherapy OR LAM plus Li for severe non-psychotic depression with a history of AD-induced mania or rapid cycling
TMAP		Monotherapy VPA, ARP, RIS, ZIP			Monotherapy Li, VPA, ARP, QTP, RIS, ZIP		LAM plus anti-manic agent if recent and/or severe history of mania, all other patients LAM monotherapy

Abbreviation: AP, Antipsychotic; MS, Traditional Mood Stabilizer (carbamazepine, divalproex, lithium); Li, Lithium; VPA, Valproate; ARP, Aripiprazole; QTP, Quetiapine; RIS, Risperidone; ZIP, Ziprasidone; LAM, Lamotrigine; AD, Antidepressant.

Discussion:

there is an incentive in the data that has been accounted for in these examination discoveries. These examinations give pragmatic practice data on changing over from DR to ER in clinical settings and what can be normal as far as viability, passableness, and helpful medication observing. While there is no information showing that the ER definition gives any upgraded viability over DR there is likewise no convincing information proposing there is a hazard to utilizing the ER over the DR. detailing. The present treatment rules incorporated into this audit don't particularly suggest the ER plan and from a proof point of view one can't state there is sufficiently solid

confirmation to settle on it a first-line decision over other treatment choices. In any case, given that the atom is the same (divalproex) and that the essential contrasts are rate of discharge and a diminished pinnacle focus, the ER detailing ought to be viewed as a sheltered other option to DR, especially when there is a history or worry of dosage related (top fixation) unfriendly occasions or when once multi day dosing is favored with an end goal to improve consistence. [76]

Conclusion:

Doctors often encounter depressed patients Experiencing schizophrenia patients with nervousness or varying. A patient with a degree of weakness or displaying symptoms An anxiety that cannot be called unequivocal. DSM IV has not given clear guidelines for such classification Cases. Panic attack in a depression patient invited two comorbid diagnoses. Specifies longitudinal syllabus DSM IV or DSM IV TR did not clearly have schizophrenia Symptomatic separation of schizophrenia patient A patient experiences flower symptoms. Carelessly The juvenile was often a clinical dilemma. Dimensional The DSM5 approach magnitudes of individual traits. Dimensional model helps grade and chart Course of the disorder. Thus it is different from normal Is unusual. It can be used as a mechanism on the screen Can be used as or for mental disorders in the general population A tool to study the generality of mental.

References:

1. Kessler RC, Bergland P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62:593–602. [PubMed]
2. Ghaemi SN. Bipolar disorder and antidepressants: an ongoing controversy. Primary Psychiatry. 2001;8(2):28–34.
3. Prien RF, Potter WZ. NIMH workshop report on treatment of bipolar disorder. Psychopharmacol Bull. 1990; 26:409–27. [PubMed]
4. Quanbeck CD, Stone DC, Scott CL, et al. Clinical and legal correlates of inmates with bipolar disorder at time of criminal arrest. J Clin Psychiatry. 2004; 65:198–203. [PubMed]
5. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar disorder. Arch Gen Psychiatry. 2002;59:530–7. [PubMed]
6. Hilty DM, Brady KT, Hales RE. Bipolar disorder in adults: A review of recent literature. Psychiatric Services. 1999; 50:201–13. [PubMed]
7. Belmaker RH. Bipolar disorder. N Eng J Med. 2004; 351:476–86. [PubMed]
8. Chang KD, Ketter TA. Special issues in the treatment of paediatric bipolar disorder. ExpOp in Pharmacother. 2001;2(4):613–22. [PubMed]
9. Hirschfeld RMA, Bowden CL, Gitlin MJ, et al. Practice guideline for the treatment of patients with bipolar disorder (revision) [April 14, 2006]; Am J Psychiatry. 2002 159(Suppl):1–35. Available at: www.psych.org/psych_pract/treatg/pg/prac_guide.cfm.
10. Sachs GS. Decision tree for the treatment of bipolar disorder. J Clin Psychiatry. 2003;64(Suppl 5):35–40. [PubMed]
11. Glick ID, Suppes T, DeBattista C, et al. Pharmacologic treatment strategies for depression, bipolar disorder, and schizophrenia. Ann Int Med. 2001;134:47–60. [PubMed]
12. Suppes T, Dennehy EB, Hirschfeld RMA, et al. Texas implementation of medication algorithms: Update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 2005;66:870–86. [PubMed]
13. *BMJ* 2012; 345 doi: https://doi.org/10.1136/bmj.e8508 (Published 27 December 2012) Cite this as: BMJ 2012;345:e8508.
14. doi:10.1136/bmj.e8508. PMID 23271744.
15. American Psychiatry Association (2013). *Diagnostic and Statistical Manual of Mental Disorders* (5th ed.). Arlington: American Psychiatric Publishing. pp. 123–154. ISBN 0-89042-555-8.
16. Fisahn, A. (2005). Kainate receptors and rhythmic activity in neuronal networks: hippocampal gamma oscillations as a tool. *J. Physiol.* 562, 65–72. doi: 10.1113/jphysiol.2004.077388.
17. Lish JD, Dime-Meenan S, Whybrow PC, et al. The National Depressive and Manic-Depressive Association (DMDA) survey of bipolar members. J Affect Disord. 1994;31:281–94. [PubMed]
18. Matza LS, Rajagopalan KS, Thompson CL, de Lissovoy G. Misdiagnosed patients with bipolar disorder: Comorbidities, treatment patterns, and direct treatment costs. J Clin Psychiatry. 2005;66(11):1432–40. [PubMed]
19. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York, NY: Oxford University Press; 1990.
20. Reus VI, Freimer NB. Understanding the genetic basis of mood disorders: Where do we stand? Am J Human Gen. 1997;60:1283–8. [PMC free article] [PubMed]
21. Fisahn, A. (2005). Kainite receptors and rhythmic activity in neuronal networks:

hippocampal gamma oscillations as a tool. *J. Physiol.* 562, 65–72. Doi: 10.1113/jphysiol.2004.077388

22. Normann, C., Hummel, B., Scharer, L. O., Horn, M., Grunze, H., and Walden, J. (2002). Lamotrigineas adjunct to paroxetinein acuted expression: a placebo-controlled, double-blind study. J. Clin. Psychiatry 63, 337–344. doi: 10.4088/JCP. v63n0411
23. Vinod, K. Y., and Subhash, M. N. (2002). Lamotrigine induced selective changes in 5-HT1A receptor mediated response in rat brain. Neurochem. Int. 40, 315–319. doi:10.1016/S0197-0186(01)00088-2.
24. Lopez-Figueroa, A. L., Norton, C. S., Lopez-Figueroa, M. O., Armellini-Dodel, D., Burke, S., Akil, H., et al. (2004). Serotonin5-HT1A,5-HT1B and 5-HT2A, recept or mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biol. Psychiatry 55, 225–233. doi: 10.1016/j.biopsych.2003.09.017.
25. Machado-Vieira, R., Kapczinski, F., and Soares, J. C. (2004). Perspectives for the development of animal models of bipolardisorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 28, 209–224. doi:10.1016/j. pnpbp.2003.10.015
26. Bourin, M., Lambert, O., and Guitton, B. (2005). Treatment of acutemania-from clinical trials to recommendations for clinical practice. Hum. Psychopharmacol. Clin. Exp. 20, 15–26. doi:10.1002/hup.657.
27. Vinod, K. Y., and Subhash, M. N. (2002). Lamotrigine induced selective changes in 5-HT1A receptor rmediated response in rat brain. Neurochem. Int. 40, 315–319. doi:10.1016/S0197-0186(01)00088-2.
28. Kaster, M. P., Raupp, I., Binfaré, R. W., Andreatini, R., and Rodrigues, A. L. (2007). Antidepressant-likeeffectoflamotrigineinthemouseforcedswimmingtest: evidence for the involvement of the noradrenergic system. Eur. J. Pharmacol. 565, 119–124. doi:10.1016/j. ejphar.2007.03.003
29. Delgado, P. L., Miller, H. L., Salomon, R. M., Licinio, J., Heninger, G. R., Gelenberg, A. J., et al. (1993). Monoamines and the mechanism of anti depressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol. Bull. 29, 389–396.
30. Southam, E., Kirkby, D., Higgins, G. A., and Hagan, R. M. (1998). Lamotrigine inhibits monoamine uptake invitero and modulates5-hydroxytryptamineuptake in rats. Eur. J. Pharmacol. 358, 19–24. doi:10.1016/S0014-2999(98)00580-9.
31. Sukul, N. C., Cherian, L., and Klemm, W. R. (1988). Alpha noradrenergic agonists promotecatalepsyin the mouse. Pharmacol. Biochem. Behav. 31, 87–91.doi: 10.1016/0091-3057(88)90316-4
32. Keck PE, Jr, McElroy SL. Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. J Clin Psychiatry. 2002; 63(Suppl 4):3–1. [PubMed]
33. Peck AW. Clinical pharmacology of lamotrigine. Epilepsia. 1991; 32(Suppl 2): S9–12. [PubMed]
34. Sinz MW, Remmel RP. Isolation and characterization of a novel quaternary ammonium-linked glucuronide of lamotrigine. Drug Metab Dispos. 1991;19:149–53.
35. Ketter TA, Manji HK, Post RM. Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J Clin Psychopharmacol. 2003;23:484–95. [PubMed]
36. Vieta, E., and Suppes, T. (2008). Bipolar II disorder: arguments for and against a distinct diagnostic entity. Bipolar Disord.10, 163–178. doi: 10.1111/j.1399 5618.2007.00561.x
37. Souery, D., Oswald, P., Massat, I., Bailer, U., Bollen, J., Demyttenaere, K., et al. (2007). Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J. Clin. Psychiatry 68, 1062–1070. doi: 10.4088/JCP.v68n0713
38. Daban, C., Martinez-Aran, A., Torrent, C., Sanchez-Moreno, J., Goikolea, J. M., Benabarre, A., et al. (2006). Cognitive functioning in bipolar patients receiving lamotrigine: preliminary results. J. Clin. Psychopharmacol.26, 178–181. doi:10.1097/01.jcp.0000204332.64390.f3
39. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003;290:1467–1473. [PubMed: 13129986]
40. Manji HK, Lenox RH. Signaling: cellular insights into the pathophysiology of bipolar disorder. Biol Psychiatry 2000;48:518–530. [PubMed: 11018224]
41. Jope RS. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 2003;24:441–443. [PubMed: 12967765]
42. Benedetti F, Serretti A, Colombo C, Lorenzi C, Tubazio V, Smeraldi E. A glycogen synthase kinase3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar

depression. Neurosci Lett 2004;368:123–126. [PubMed:15351432]
43. Gould TD, Zarate CA, Manji HK. Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. J Clin Psychiatry 2004;65:10–21. [PubMed: 14744163]
44. Jope RS, Roh MS. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets 2006;7:1421–1434. [PubMed: 17100582]
45. dChin PC, Majdzadeh N, D'Mello SR. Inhibition of GSK3beta is a common event in neuroprotection by different survival factors. Brain Res Mol Brain Res 2005;137:193–201. [PubMed: 15950778]
46. Bijur GN, De Sarno P, Jope RS. Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium. J Biol Chem 2000;275:7583–7590. [PubMed:10713065]
47. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 1996;93:8455–8459. [PubMed: 8710892]
48. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003;423:435–439. [PubMed: 12761548]
49. Exhibited that thumping out a solitary duplicate of the GSK-3β quality in mice brought about upper like impacts that were similar to lithium organization. Additionally, fringe organization of a GSK-3 inhibitor decreased amphetamine-incited hyperactivity.
50. Silverstone P., McGrath B., Kim H. (2005) Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings. Bipolar Disord 7: 1–10 [PubMed]
51. Berridge M., Downes C., Hanley M. (1989) Neural and developmental actions of lithium - a unifying hypothesis. Cell 59: 411–419 [PubMed]
52. Phiel C., Klein P. (2001) Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 41: 789–813 [PubMed]
53. Phiel C., Klein P. (2001) Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 41: 789–813 [PubMed]
54. Haimovich A., Eliav U., Goldbourt A. (2012) Determination of the lithium binding site in inositol monophosphatase, the putative target for lithium therapy, by magic-angle-spinning solid-state NMR. J Am Chem Soc 134: 5647–5651 [PubMed]
55. Stahl S. (2008) Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 3rd edn (Essential Psychopharmacology Series). Cambridge: Cambridge University Press.
56. Hawkins SB, Bucklin M, Muzyk AJ. Quetiapine for the treatment of delirium. J Hosp Med. 2013;8:215–220. doi: 10.1002/jhm.2019. [PubMed]
57. Sanford M. Quetiapine extended release: adjunctive treatment in major depressive disorder. CNS Drugs. 2011;25:803–813. doi: 10.2165/11207280-000000000-00000. [PubMed]
58. Plosker GL. Quetiapine: a pharmacoeconomic review of its use in bipolar disorder. Pharmacoeconomics. 2012;30:611–631. doi: 10.2165/11208500-000000000-00000. [PubMed]
59. López-Muñoz F, Alamo C. Active metabolites as anti-depressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders. Front Psychiatry. 2013;4:102. doi: 10.3389/fpsyt.2013.00102.
60. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry. 2000;57:553–559. doi: 10.1001/archpsyc.57.6.553.
61. Mundo E, Cattaneo E, Zanoni S, Altamura AC. The use of atypical antipsychotics beyond psychoses: efficacy of quetiapine in bipolar disorder. Neuropsychiatr Dis Treat. 2006;2:139–148. doi: 10.2147/nedt.2006.2.2.139.
62. Rasmussen H, Ebdrup BH, Aggernaes B, Lublin H, Oranje B, Pinborg LH, et al. Norquetiapine and depressive symptoms in initially antipsychotic-naive first-episode schizophrenia. J Clin Psychopharmacol. 2013;33:266–269. doi: 10.1097/JCP.0b013e318287acc9.
63. Silverstone PH, Lalies MD, Hudson AL. Quetiapine and Buspirone Both Elevate Cortical Levels of Noradrenaline and Dopamine In vivo, but Do Not have Synergistic Effects. Front Psychiatry. 2012;3:82. doi: 10.3389/fpsyt.2012.00082.
64. Sümegi A. Quetiapin in bipolar disorders. Neuropsychopharmacol Hung. 2008;10:281–291.
65. Stahl SM, Lee-Zimmerman C, Cartwright S, Morrissette DA. Serotonergic drugs for depression and beyond. Curr Drug Targets. 2013;14:578–585. doi: 10.2174/1389450111314050007
66. Hauge-Evans AC, Reers C, Kerby A, Franklin Z, Amisten S, King AJ, et al. Effect of hyperglycaemia on muscarinic M3 receptor expression and secretory sensitivity to cholinergic receptor activation in islets. Diabetes

Obes Metab. 2014;16:947–956. doi: 10.1111/dom.12301
67. Ketter TA. Acute and maintenance treatments for bipolar depression. J Clin Psychiatry. 2014;75:e10. doi: 10.4088/JCP.13010tx2c.
68. Lev-Ran S, Le Foll B, McKenzie K, George TP, Rehm J. Bipolar disorder and co-occurring cannabis use disorders: characteristics, co-morbidities and clinical correlates. Psychiatry Res. 2013;209:459–465. doi: 10.1016/j.psychres.2012.12.014.
69. Latalova K, Kamaradova D, Prasko J. Suicide in bipolar disorder: a review. Psychiatr Danub. 2014;26:108–114.
70. Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, et al. EMBOLDEN I (Trial 001) Investigators. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I) J Clin Psychiatry. 2010;71:150–162. doi: 10.4088/JCP.08m04995gre
71. Suppes T, Vieta E, Gustafsson U, Ekholm B. Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar I disorder: analysis of two large randomized, placebo-controlled trials. Depress Anxiety. 2013;30:1089–1098. doi: 10.1002/da.22136.
72. Loscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs. 2002;16:669–94.
73. Abbott Laboratories. Depakote ER® package insert. North Chicago, IL: Jan, 2006b.
74. Bowden CL, Gitlin MJ, Keck PE, et al. Practice Guideline for the treatment of subjects with bipolar disorder (revision) Am J Psychiatry. 2002;159(April Suppl):1–50.
75. Stoner SC, Dubisar BM, Lea JW, et al. Extended-release divalproex sodium for mood stabilization. Pharmacotherapy. 2004;24:1147–53.
76. Steven C Stoner, Megan M Dahmen Neuropsychiatr Dis Treat. 2007 Dec; 3(6): 839–846.

9/25/2020